Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, U.S. February 1–September 30, 2021

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Bajema, Kristina L. ; Dahl, Rebecca M. ; Evener, Steve L. ; Prill, Mila M. ; Rodriguez-Barradas, Maria C. ; Marconi, Vincent C. ; Beenhouwer, David O. ; Holodniy, Mark ; Lucero-Obusan, Cynthia ; Brown, Sheldon T. ; Tremarelli, Maraia ; Epperson, Monica ; Mills, Lisa ; Park, So Hee ; Rivera-Dominguez, Gilberto ; Morones, Rosalba Gomez ; Ahmadi-Izadi, Ghazal ; Deovic, Rijalda ; Mendoza, Chad ; Jeong, Chan ; Schrag, Stephanie J. ; Meites, Elissa ; Hall, Aron J. ; Kobayashi, Miwako ; McMorrow, Meredith ; Verani, Jennifer R. ; Thornburg, Natalie J. ; Surie, Diya ; Burnette, Joy ; Capo, Gustavo ; Epstein, Lauren ; Gallini, Julia ; Harrison, Telisha ; Hartley, Amy ; Hernandez, Liliana ; Morales, Elena ; Patel, Nina ; Rooney, Kim ; Tanner, Tehquin ; Tate, Ernest ; Tunson, Ashley ; Whitmire, Alexis ; Winston, Juton ; Elliot, Katherine ; Graham, Ilda ; Lama, Diki ; Pena, Ismael ; Perea, Adrienne ; Perez, Guerry Anabelle ; Simelane, Johane ; Smith, Sarah ; Tallin, Gabriela ; Tisi, Amelia ; Lopez, Alonso Arellano ; Gonzalez, Miguel Covarrubias ; Lengi, Bashir ; Tamez, Mariana Vanoye ; Aryanfar, Babak ; Lee-Chang, Ian ; Matolek, Anthony ; Poteshkina, Aleksandra ; Naeem, Saadia ; Goldin, Evan ; Agrawal, Madhuri ; Lopez, Jessica ; Peters, Theresa ; Kudryavtseva, Geliya ; Cates, Jordan ; Kambhampati, Anita
• Corporate Authors:
  SUPERNOVA COVID-19 Surveillance Group ; Surveillance Platform for Enteric and Respiratory Infectious Organisms at the VA (SUPERNOVA) ; COVID-19 Surveillance Group
• Description:
  The mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) provide strong protection against severe COVID-19, including hospitalization, for at least several months after receipt of the second dose (1,2). However, studies examining immune responses and differences in protection against COVID-19-associated hospitalization in real-world settings, including by vaccine product, are limited. To understand how vaccine effectiveness (VE) might change with time, CDC and collaborators assessed the comparative effectiveness of Moderna and Pfizer-BioNTech vaccines in preventing COVID-19-associated hospitalization at two periods (14-119 days and ≥120 days) after receipt of the second vaccine dose among 1,896 U.S. veterans at five Veterans Affairs medical centers (VAMCs) during February 1-September 30, 2021. Among 234 U.S. veterans fully vaccinated with an mRNA COVID-19 vaccine and without evidence of current or prior SARS-CoV-2 infection, serum antibody levels (anti-spike immunoglobulin G [IgG] and anti-receptor binding domain [RBD] IgG) to SARS-CoV-2 were also compared. Adjusted VE 14-119 days following second Moderna vaccine dose was 89.6% (95% CI = 80.1%-94.5%) and after the second Pfizer-BioNTech dose was 86.0% (95% CI = 77.6%-91.3%); at ≥120 days VE was 86.1% (95% CI = 77.7%-91.3%) for Moderna and 75.1% (95% CI = 64.6%-82.4%) for Pfizer-BioNTech. Antibody levels were significantly higher among Moderna recipients than Pfizer-BioNTech recipients across all age groups and periods since vaccination; however, antibody levels among recipients of both products declined between 14-119 days and ≥120 days. These findings from a cohort of older, hospitalized veterans with high prevalences of underlying conditions suggest the importance of booster doses to help maintain long-term protection against severe COVID-19.|.
• Subjects:
  2019-nCoV Vaccine MRNA-1273 Aged Antibodies, Viral BNT162 Vaccine Cohort Studies CoronaVirus Infections COVID-19 Female Hospitalization Humans Immunization Schedule Male Middle Aged Patient Acuity SARS-CoV-2 Time Factors Vaccine Efficacy Veterans Veterans Health Services

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 70(49):1700-1705
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/MMWRmm7049a2
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  34882654
• Pubmed Central ID:
  PMC8659185
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  6 pdf pages
• Volume:
  70
• Issue:
  49
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:af56553dede13f51a317b28e6c95075785f4df2cfe946fd34f4acaddb364da694e26739dae175b9e23b3a856e06879d3e93acaac94229c1d9df448fc45abff6c
• Download URL:
  https://stacks.cdc.gov/view/cdc/113650/cdc_113650_DS1.pdf
• File Type:
  [PDF - 329.27 KB ]